https://cdnph.upi.com/ph/st/th/7651780053770/2026/i/17800541626481/v1.5/Celltrion-develops-quadruple-action-obesity-drug.jpg" /> South Korea's biopharmaceutical company Celltrion said Friday that it has begun primate toxicology studies for CT-G32, its next-generation obesity drug candidate, as the final preclinical stage before human trials.